AIBN Virtual Seminar Series: Systems biology to understand the production of bio-therapeutics in CHO cells by removing clonal variation
Event Details
- Date:
- Thursday, 27 August 2020 - Thursday, 27 August 2020
- Time:
- 12:00 pm - 12:45 pm
- Room:
- Via Zoom Only
- URL:
- https://uqz.zoom.us/webinar/register/WN_b6kqLRs5ScyJPUkJQoKYmw
- Event category(s):
Event Contact
- Name:
- Ms Kahlia Bartley
- Phone:
- 64215
- Email:
- aibn.events@uq.edu.au
- Org. Unit:
- Australian Institute for Bioengineering and Nanotechnology
Event Description
- Full Description:
- Bio-therapeutics are drugs or vaccines derived from living systems used to treat many diverse diseases, including cancers, diabetes, haemophilia, and arthritis. In 2019, almost 50% of new drugs approved by the Food and Drug Administration were bio-therapeutics. Of those new bio-therapeutics, 70% were made in Chinese Hamster Ovary (CHO) cells making CHO cells the producer of over a quarter of all new drugs. Due to the heavy reliance on CHO cells, considerable research has gone into understanding how they express bio-therapeutics. Past research has focused on improving culture processes through media, bio-reactors, vector optimisation, and targeted engineering. Whilst these improvements have been highly successful, a ceiling has been hit limiting useful production improvements. Systems biology offers a way to break through the ceiling to gain larger production titres in CHO cells. Systems biology treats CHO cells as a complex interactive system gathering results on computational and mathematical modelling/analysis from experimental data obtained from various omics techniques. By using systems biology, we want to understand why the model bio-therapeutic Factor IX is expressed in relatively small quantities compared to other bio-therapeutics
Unfortunately, CHO cells have large amounts of clonal variation caused by rigorous selection, random integration of transgenes, and CHO’s unstable genome. The variation means any systems biology results seen might be attributed to the clonal variation between cell lines rather than bio-therapeutic production. Utilising the synthetic biology tools CRISPR and ‘landing-pads’ in combination with cell line development equipment such as the Beacon, we have created cell lines with reduced clonal variation to achieve better systems biology results to understand Factor IX production in CHO cells.
Presenter: Aiden Beauglehole, AIBN PhD Student, Mahler Group
Aiden completed his undergraduate degree in Zoology at the University of Melbourne. He then went on to complete his Masters of Biotechnology at RMIT. Whilst at RMIT, he completed research projects on cell line engineering of HEK293 cells using CRISPR and researching anaesthetic mechanism of action utilising Gloeobacter ligand-gated ion channels. After graduation, Aiden worked as a Lab Technician at QUT for a year before starting his PhD at the Centre for Biopharmaceutical Innovation in the AIBN. Aiden’s PhD project is in collaboration with CBI industry partner CSL where he recently completed 8 months of industry placement. Aiden’s project aims to use systems biology-guided cell-line engineering for production of therapeutic proteins with complex post-translational modification in CHO cells.
Event Tools
Share This Event
Print
Email
Share
